Jan 4, 2021
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis of Berubicin’s performance against lomustine, the chemotherapy standard of care drug. “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” CMO Dr. Sandra Silberman said during the webinar.
To view the full article, visit https://ibn.fm/jqKgo
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
Travel AND dessert; what could be better? View Entire Post ›
Autumn is a popular season for hiking in Hong Kong, offering crisp air and sweeping vistas across the countryside. Yet beyond leisure, October brings a significant cultural occasion to climb the hills: the annual Chung Yeung Festival, which falls on October 18 this year. The name of the festival, which translates to “double yang” in Chinese, originates from its occurrence on the ninth day of the ninth lunar month. This numerical alignment also gives the occasion its alternative title, the Double...
Test your knowledge of geography! View Entire Post ›
Next stop: somewhere new. View Entire Post ›
For a sporting event steeped in British tradition, the Boat Race has always been as much about ritual as competition. In 2027, that history will meet a distinctly Chanel interpretation, as the maison introduces new trophies for the winning Oxford and Cambridge crews, marking both a new chapter in its partnership with the race and the centenary of the first Women’s Boat Race. The 2027 edition will be the third year of the Chanel J12 Boat Race, with the maison serving as title sponsor and...
I guarantee your mouth will be watering at the end of this quiz. View Entire Post ›
The bucket-list destination you didn't know you needed. View Entire Post ›
Growing up in Hong Kong in a family of architects and interior designers, Emma Maclean was practically destined for a career in the field. Today her Sheung Wan-based studio – first started in 2018 as EM Bespoke before relaunching under the name Emma Maclean & Co in 2024 – creates spaces that reflect the remarkable contrasts that make this city eternally exciting for designers, where old and new, East and West, glistening skyscrapers and natural waters all somehow coexist in harmony. “I feel Hong...
Would you trust your husband to fully renovate your home, without any design input from you? Rachel Tong did. She did not even visit the flat, which took 10 months to redo, until a few days before completion. Fortunately for her, designer Nicole Cromwell of Nicole Cromwell Interior Design was a major factor in the concept, guaranteeing that the 1,000 sq ft (93 square metre) flat, with an equally large private terrace, would be a stylish affair. Tong and her husband Paul had lived in their...
The E190 was too large to be a regional jet, too small to thrive at mainline costs and eventually outclassed by the A220. America’s awkward middle child finally exits. The post Opinion: What Killed the Embraer E190 in the United States? appeared first on Business Traveller.
A writer’s road trip in search of the early Renaissance master’s most resplendent works takes her to towns beyond Florence, the birthplace of the Italian Renaissance.
Immanuel Presbyterian, featured in the My Chemical Romance video "Helena," is inviting people to attend its new October series pairing My Chemical Romance lyrics and Christianity.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.